| Autor: |
Murashko LE, Sheveleva GA, Strel'chenko NV, Filimonov VG, Sidel'nikova VM |
| Jazyk: |
ruština |
| Zdroj: |
Akusherstvo i ginekologiia [Akush Ginekol (Mosk)] 1992 (8-12), pp. 24-7. |
| Abstrakt: |
Clinical and experimental studies have revealed that salbupart, a beta-mimetic agent, administered in a dose of 0.14 mg/kg (the maximal therapeutic dose) markedly inhibited the spontaneous and oxytocin-induced uterine contractility, caused no embryotoxic or teratogenic effects, and did not influence fetal growth and development. The efficacy of salbupart tocolytic therapy was estimated as 75%. Blood plasma cAMP levels normalized in the pregnant women over the course of therapy. Clinical and experimental results recommend salbupart for pregnancy protecting therapy in cases with threatened spontaneous abortions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
